Second Sight Medical Products (EYES) Earns Daily Media Impact Rating of 0.20

Press coverage about Second Sight Medical Products (NASDAQ:EYES) has been trending somewhat positive this week, Alpha One Sentiment reports. Alpha One, a subsidiary of Accern, identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Second Sight Medical Products earned a media sentiment score of 0.20 on Alpha One’s scale. Alpha One also gave media coverage about the medical device company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Alpha One Sentiment Analysis’s analysis:

Shares of Second Sight Medical Products (NASDAQ:EYES) remained flat at $1.17 during trading on Thursday. The company had a trading volume of 429,304 shares. The stock’s market cap is $65.95 million. Second Sight Medical Products has a one year low of $1.06 and a one year high of $6.05. The company has a 50-day moving average of $1.29 and a 200-day moving average of $1.92.

Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings data on Thursday, March 9th. The medical device company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. Second Sight Medical Products had a negative return on equity of 121.31% and a negative net margin of 502.22%. The firm earned $0.72 million during the quarter, compared to the consensus estimate of $1.76 million. During the same period in the previous year, the firm earned ($0.13) EPS. The business’s revenue was down 70.2% on a year-over-year basis. On average, analysts expect that Second Sight Medical Products will post ($0.54) EPS for the current year.

Separately, HC Wainwright set a $16.00 price objective on shares of Second Sight Medical Products and gave the stock a “buy” rating in a research note on Sunday, December 25th.

WARNING: This story was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at

In other news, Director Gregg Williams acquired 4,000,000 shares of the business’s stock in a transaction that occurred on Friday, April 7th. The stock was bought at an average price of $1.00 per share, with a total value of $4,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 34.70% of the company’s stock.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

5 Day Chart for NASDAQ:EYES

This story was originally published by WKRB News ( and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Second Sight Medical Products Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc and related companies with's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.